Art. -Nr.: HY-15425

PF-543

(Synonyms: Sphingosine Kinase 1 Inhibitor II)

28 Cited Publications

Kundenbewertung

Based on 28 publication(s) in Google Scholar

PF-543 (Sphingosine Kinase 1 Inhibitor II) is a potent, selective, reversible and sphingosine-competitive SPHK1 inhibitor with an IC₅₀ of 2 nM and a K_i of 3.6 nM. PF-543 is >100-fold selectivity for SPHK1 over SPHK2. PF-543 is an effective potent inhibitor of sphingosine 1-phosphate (S1P) formation in whole blood with an IC₅₀ of 26.7 nM. PF-543 induces apoptosis, necrosis, and autophagy.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.85%
CAS. Nr.: 1415562-82-1
Formel: C₂₇H₃₁NO₄S
Molecular Weight:465.60

Speicherung:

-20°C, protect from light, stored under nitrogen

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)

PF-543 Chemical Structure

CAS. Nr.: 1415562-82-1

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (28)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

SphK1

Alle SphK Isoform-spezifische Produkte anzeigen :

SphK1
SphK2

Alle LPL Receptor Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
HEK293	IC₅₀	28 nM Compound: 1; PF-543	Inhibition of GFP-tagged SK1 (unknown origin) expressed in HEK293 cells using Sph as substrate measured after 30 mins in presence of [gamma32P]ATP by Cerenkov counting analysis Inhibition of GFP-tagged SK1 (unknown origin) expressed in HEK293 cells using Sph as substrate measured after 30 mins in presence of [gamma32P]ATP by Cerenkov counting analysis	[PMID: 30889352]
HT-29	IC₅₀	13.02 μM Compound: PF-543; 4	Antiproliferative activity against human HT-29 cells incubated for 72 hrs by SRB assay Antiproliferative activity against human HT-29 cells incubated for 72 hrs by SRB assay	[PMID: 35439002]
MCF7	IC₅₀	16.23 μM Compound: PF-543	Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 37586181]
MDA-MB-231	IC₅₀	27.12 μM Compound: PF-543; 4	Antiproliferative activity against human MDA-MB-231 cells for 72 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells for 72 hrs by SRB assay	[PMID: 35439002]
MGC-803	IC₅₀	51.66 μM Compound: PF-543	Antiproliferative activity against human MGC-803 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Antiproliferative activity against human MGC-803 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 37586181]
PC-3	GI₅₀	19 μM Compound: 5; PF-543	Antiproliferative activity against human PC3 cells after 72 hrs by MTS assay Antiproliferative activity against human PC3 cells after 72 hrs by MTS assay	[PMID: 26780304]
Sf9	IC₅₀	>5000 nM Compound: 1; PF-543	Inhibition of recombinant human full-length N-terminal His-tagged SK2 expressed in baculovirus infected Sf9 insect cells using Sph as substrate measured after 30 mins in presence of [gamma32P]ATP by Cerenkov counting analysis Inhibition of recombinant human full-length N-terminal His-tagged SK2 expressed in baculovirus infected Sf9 insect cells using Sph as substrate measured after 30 mins in presence of [gamma32P]ATP by Cerenkov counting analysis	[PMID: 30889352]
U-937	IC₅₀	30.72 μM Compound: PF-543	Antiproliferative activity against human U-937 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Antiproliferative activity against human U-937 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 37586181]

In Vitro

PF-543 (10-1000 nM; 24?hours; PASM cells) treatment abolishes SK1 expression at nM concentrations^[2].
? PF-543 (0.1-10 μM; 24 hours; PASM cells) treatment induces caspase-3/7 activity^[2].
? PF-543 inhibits C₁₇-S1P formation in 1483 cells with an IC₅₀ of 1.0 nM^[1].
? SphK1 inhibition by PF-543 causes a dose-dependent depletion of the intracellular level of S1P with EC₅₀ concentration of 8.4 nM and a concomitant elevation of the intracellular level of sphingosine in 1483 cells. The level of endogenous S1P in 1483 cells after a 1 h treatment with 200 nM PF-543 is decreased 10-fold, producing a proportional increase in the level of sphingosine^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[2]

Cell Line:

Human pulmonary arterial smooth muscle (PASM) cells
Concentration:

10 nM, 100 nM, 1000 nM
Incubation Time:

24 hours
Result:

Abolished SK1 expression at nM concentrations.

Apoptosis Analysis^[2]

Cell Line:

Human pulmonary arterial smooth muscle (PASM) cells
Concentration:

0.1 μM, 1 μM, 10 μM
Incubation Time:

24 hours
Result:

Induced caspase-3/7 activity in cultured human pulmonary smooth muscle cells.

In Vivo

PF-543 (1 mg/kg; intraperitoneal injection; every second day; for 21 days; female C57BL/6 J mice) treatment has no effect on vascular remodelling but reduces right ventricular hypertrophy. The protection involves a reduction in the expression of p53 and an increase in the expression of anti-oxidant nuclear factor Nrf-2^[2].
? Mice are initially dosed (ip) with 10 mg/kg or 30 mg/kg of PF-543 for 24 h and the T_1/2 is 1.2 h in blood samples. Administration of 10 mg/kg PF-543 for 24 h to mice induces a decrease in SK1 expression in pulmonary vessels^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Female C57BL/6 J mice (7-12 week-old) with hypoxic-induced pulmonary arterial hypertension^[2]
Dosage:

1 mg/kg
Administration:

Intraperitoneal injection; every second day; for 21 days
Result:

Reduced right ventricular hypertrophy. The protection involves a reduction in the expression of p53 (that promotes cardiomyocyte death) and an increase in the expression of anti-oxidant nuclear factor Nrf-2.

Chemical Information

CAS. Nr. 1415562-82-1
Appearance Solid
Molecular Weight 465.60
Formel C₂₇H₃₁NO₄S
Color White to off-white
SMILES

CC1=CC(OCC2=CC=C(CN3[C@@H](CO)CCC3)C=C2)=CC(CS(C4=CC=CC=C4)(=O)=O)=C1
Synonyms

Sphingosine Kinase 1 Inhibitor II
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

-20°C, protect from light, stored under nitrogen

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)

Publications (28)

All RT-PCRBio/Physico-chemical AssayIn Vivo Efficacy StudyIF

Sort by:

Journal Impact Factor

Cell Metab

Adipokine IL-11/IL-11Ra constrains sphingolipid metabolism to limit the thermogenic capacity of beige adipocytes. [Abstract]

2026 May 14:S1550-4131(26)00151-8. PMID: 42140185
Cancer Commun (Lond)

Targeting SPHK1 in macrophages remodels the tumor microenvironment and enhances anti-PD-1 immunotherapy efficacy in colorectal cancer liver metastasis. [Abstract]

2025 Jul 16. PMID: 40665874

PF-543 purchased from MedChemExpress. Usage Cited in: Cancer Commun (Lond). 2025 Jul 16. [Abstract]

Relative mRNA expression of inflammasome genes in TAMs from liver tumors with or without PF-543 (5 mg/kg; i.p.) treatment were determined by qPCR.

PF-543 purchased from MedChemExpress. Usage Cited in: Cancer Commun (Lond). 2025 Jul 16. [Abstract]

Representative images and relative levels of IL-1β and CXCL9 in Ctrl- and PF-543-treated liver tumors determined by a mouse inflammatory cytokine array. PF-543 (5 mg/kg; i.p.) significantly decreased IL‐1β expression in TAMs compared to control group.

PF-543 purchased from MedChemExpress. Usage Cited in: Cancer Commun (Lond). 2025 Jul 16. [Abstract]

SPHK1 inhibitor PF-543 (5 mg/kg; i.p.; once every 3 d) reduced the number and diameter of liver metastatic tumors in mice.

PF-543 purchased from MedChemExpress. Usage Cited in: Cancer Commun (Lond). 2025 Jul 16. [Abstract]

Representative IF images and quantification of co-staining of p-SPHK1 (red) and F4/80 (green) in liver tumor tissues from C57BL/6 mice with or without PF-543 (5 mg/kg; i.p.; once every 3 d). PF-543 treatment decreased number of phosphorylated SPHK1⁺ TAMs (activated SPHK1) in the liver tumor microenvironment.

PF-543 purchased from MedChemExpress. Usage Cited in: Cancer Commun (Lond). 2025 Jul 16. [Abstract]

SPHK1 inhibitor PF-543 (5 mg/kg; i.p.; once every 3 d) markedly reduced the level of S1P in MC38 liver tumors.
Mol Cell

Genome-wide Screening Identifies SFMBT1 as an Oncogenic Driver in Cancer with VHL Loss. [Abstract]

2020 Mar 19;77(6):1294-1306.e5. PMID: 32023483
Pharmacol Res

Lysosome-triggered nanotherapy packages osteoclast apoptotic bodies with pro-anabolic lipids to couple anti-resorption and bone formation. [Abstract]

2026 Apr 30:108225. PMID: 42069319
Cell Death Dis

Triggering of endoplasmic reticulum stress via ATF4-SPHK1 signaling promotes glioblastoma invasion and chemoresistance. [Abstract]

2024 Aug 1;15(8):552. PMID: 39090107
Phytomedicine

Alisol A 24-acetate protects against NASH-associated fibrosis via suppression of Kupffer cell-derived SPHK1/S1P axis. [Abstract]

2025 Sep 19:148:157271. PMID: 40992063
EBioMedicine

2025 Dec 8;123:106058.
Sci China Life Sci

SPHK1 deficiency promotes intestinal homeostasis by ameliorating ER stress-induced gastrointestinal injury during murine graft-versus-host disease. [Abstract]

2026 May;69(5):1634-1649. PMID: 41627669
Sci China Life Sci

NPC1-regulated dynamic of clathrin-coated pits is essential for viral entry. [Abstract]

2022 Feb;65(2):341-361. PMID: 34047913
Chin Med J (Engl)

Sphingosine-1-phosphate induces pulmonary artery smooth muscle cell proliferation, migration and pulmonary arterial remodeling by modulating sonic hedgehog signaling effector FoxM1. [Abstract]

2026 May 5;139(9):1375-1387. PMID: 41859863
Arch Pharm Res

Sphingolipid modulation and anti-tumor activity of Jaspine B in HepG2 bearing mice. [Abstract]

2025 Aug;48(7-8):798-813. PMID: 40681917
Phytother Res

Geniposide Improves Glycolysis Driven Angiogenesis in Experimentary Arthritis by Inhibiting SphK1-PI3K-Akt-PFKFB3 Signal. [Abstract]

2025 Aug;39(8):3419-3431. PMID: 40583637
Environ Pollut

Polycyclic aromatic hydrocarbon aggravates high-fat diet-induced metabolic dysfunction-associated steatotic liver disease through disturbing hepatocyte sphingolipid metabolism. [Abstract]

2025 Jul 16:383:126846. PMID: 40681076
J Ethnopharmacol

Xianlian Jiedu Decoction induces apoptosis in colorectal cancer via modulation of sphingosine-1-phosphate-dependent JNK/p38 MAPK signaling. [Abstract]

2026 Nov 15:370:121987. PMID: 42276393
Pain

Mast cell corticotropin-releasing factor receptor 1 contributes to pancreatic cancer pain via mitogen-activated protein kinase/sphingosine kinases type 1 signaling. [Abstract]

2026 Apr 1;167(4):962-975. PMID: 41615309
Eur J Pharmacol

Inhibition of PKM2 lactylation by geniposide ameliorates synovial hyperplasia in experimental arthritis. [Abstract]

2026 May 10:1023:178866. PMID: 41990904
Inflammation

Blocking SphK1/S1P/S1PR1 Signaling Pathway Alleviates Lung Injury Caused by Sepsis in Acute Ethanol Intoxication Mice. [Abstract]

2021 Dec;44(6):2170-2179. PMID: 34109517
Chem Biol Interact

Glyoxylic acid-induced calcium oxalate crystal deposition drives nephrotoxicity via SPHK1-mediated ferroptosis: Insights from untargeted lipidomics. [Abstract]

2026 Jul 1:434:112105. PMID: 42044864
Sci Rep

Follicle-stimulating hormone promotes the proliferation of epithelial ovarian cancer cells by activating sphingosine kinase. [Abstract]

2020 Aug 14;10(1):13834. PMID: 32796926
Cancer Sci

Human alkaline ceramidase 2 promotes the growth, invasion, and migration of hepatocellular carcinoma cells via sphingomyelin phosphodiesterase acid-like 3B. [Abstract]

2020 Jul;111(7):2259-2274. PMID: 32391585
FASEB J

SPHK1/S1P/S1PR pathway promotes the progression of peritoneal fibrosis by mesothelial-mesenchymal transition. [Abstract]

2024 Jan 31;38(2):e23417. PMID: 38226856
Immunotargets Ther

2026 Jan 21;15:1-19.
Immunotargets Ther

Upregulated BLM and RECQL4 in Osteosarcoma: Association with Poor Prognosis, Immune Cell Infiltration, and Inhibitory Effects of Sphingosine Kinase 1 Inhibitor II/Pilaralisib. [Abstract]

2026 Jan 22:15:569823. PMID: 41878019
Ren Fail

Hypoxia-inducible factor 2α overexpression in podocytes ameliorates lipid metabolism disorders in diabetic kidney disease by inhibiting S1P. [Abstract]

2025 Dec;47(1):2568972. PMID: 41077842
Pflugers Arch

Sphingosine kinase 1 inhibition aggravates vascular smooth muscle cell calcification. [Abstract]

2025 Jun;477(6):815-826. PMID: 39899071
Dig Dis Sci

The Combination of PF-543 and TRAIL Effectively Induces Apoptotic Cell Death and Inhibits Stem Cell-Like Properties Through the SPHK1/S1PR1/STAT3 Pathway in TRAIL-Resistant Colorectal Cancer Cells. [Abstract]

2025 Jun 5. PMID: 40467915
Hum Cell

Sphk1 promotes ulcerative colitis via activating JAK2/STAT3 signaling pathway. [Abstract]

2020 Jan;33(1):57-66. PMID: 31606874
Curr Res Pharmacol Drug Discov

The suppression of the SPHK1/S1P/S1PR3 signaling pathway diminishes EGFR activation and increases the sensitivity of non-small cell lung cancer to gefitinib. [Abstract]

2025 Jan 9:8:100212. PMID: 39896887

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (214.78 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.1478 mL

10.7388 mL

21.4777 mL

5 mM

0.4296 mL

2.1478 mL

4.2955 mL

10 mM

0.2148 mL

1.0739 mL

2.1478 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 5 mg/mL (10.74 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 5 mg/mL (10.74 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (278 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Schnute ME, et al. Modulation of cellular S1P levels with a novel, potent and specific inhibitor of sphingosine kinase-1. Biochem J. 2012 May 15;444(1):79-88. [Content Brief]

[2]. MacRitchie N, et al. Effect of the sphingosine kinase 1 selective inhibitor, PF-543 on arterial and cardiac remodelling in a hypoxic model of pulmonary arterial hypertension. Cell Signal. 2016 Aug;28(8):946-55. [Content Brief]

[3]. Hamada M, et al. Induction of autophagy by sphingosine kinase 1 inhibitor PF-543 in head and neck squamous cell carcinoma cells. Cell Death Discov. 2017 Aug 14;3:17047. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.1478 mL	10.7388 mL	21.4777 mL	53.6942 mL
	5 mM	0.4296 mL	2.1478 mL	4.2955 mL	10.7388 mL
	10 mM	0.2148 mL	1.0739 mL	2.1478 mL	5.3694 mL
	15 mM	0.1432 mL	0.7159 mL	1.4318 mL	3.5796 mL
	20 mM	0.1074 mL	0.5369 mL	1.0739 mL	2.6847 mL
	25 mM	0.0859 mL	0.4296 mL	0.8591 mL	2.1478 mL
	30 mM	0.0716 mL	0.3580 mL	0.7159 mL	1.7898 mL
	40 mM	0.0537 mL	0.2685 mL	0.5369 mL	1.3424 mL
	50 mM	0.0430 mL	0.2148 mL	0.4296 mL	1.0739 mL
	60 mM	0.0358 mL	0.1790 mL	0.3580 mL	0.8949 mL
	80 mM	0.0268 mL	0.1342 mL	0.2685 mL	0.6712 mL
	100 mM	0.0215 mL	0.1074 mL	0.2148 mL	0.5369 mL

PF-543

28 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

PF-543

Apoptosis Compound Library

GPCR/G Protein Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Cardiovascular Disease Compound Library

Anti-Pulmonary Fibrosis Compound Library

Heterocyclic Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Multi-Target Compound Library

Bioactive Compound Library Max

Kinase Inhibitor Library Mini

MCE Bioactive Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) PF-543

Alle SphK Isoform-spezifische Produkte anzeigen

Alle LPL Receptor Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (28)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

PF-543

Apoptosis Compound Library

GPCR/G Protein Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Cardiovascular Disease Compound Library

Anti-Pulmonary Fibrosis Compound Library

Heterocyclic Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Multi-Target Compound Library

Bioactive Compound Library Max

Kinase Inhibitor Library Mini

MCE Bioactive Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) PF-543

Alle SphK Isoform-spezifische Produkte anzeigen

Alle LPL Receptor Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (28)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

PF-543 Related Classifications

HY-15425 Related Classifications